Indian pharmaceutical company Lupin announced that Dr. Shahin Fesharaki has been appointed as Global Chief Scientific Officer who will handle global research and development works across generics, branded, and specialty products.

Vinita Gupta – Lupin CEO and Lupin MD Nilesh Gupta said: “We are very pleased to welcome Shahin to our leadership team. Shahin’s exceptional track record in delivering brands and generics across developed and emerging markets will be valuable to us as we accelerate our evolution into complex generics and specialty while driving growth across all our major markets”.

Dr. Shahin Fesharaki has 30 years experience in drug development in pharmaceutical firms and worked as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals before. He previously worked in different leadership roles in Teva, Apotex, Allergan/Actavis and Watson Pharmaceuticals. He has development experience in both generic and branded pharmaceuticals across a range of technologies and dosage forms.

  Allergan, Hikma Pharmaceuticals, India, Lupin, Nilesh Gupta, Shahin Fesharaki, Vinita Gupta